News
Experimental drug teplizumab for type 1 diabetes strikingly effective...
www.upi.com
A drug designed to block the advance of type 1 diabetes in its earliest stages is strikingly effective in the phase 2 clinical trial, U.S. researchers say.
New treatment could free type-1 diabetics from 'daily grind' of...
www.independent.co.uk
Researchers hail findings as a possible 'game-changer' and 'a new way forward' for patients
UCSF Immunologist to Head New Parker Institute for Cancer...
www.ucsf.edu
Renowned UCSF immunologist Jeffrey Bluestone, PhD, has been named president and CEO of the Parker Institute for Cancer Immunotherapy, a national initiative...
Dr. Jeffrey Bluestone Archives | Rheumatoid Arthritis News
rheumatoidarthritisnews.com
A new research laboratory will be established at the UC San Francisco Diabetes Center thanks to a $10 million gift granted by The Parker Foundation.
sorted by relevance / date